PARP1 and neoplasm: PARP1 inhibition causes the so-called “synthetic lethality” in tumor cells with defective homologous recombination pathways and sensitizes tumor cells to DNA damaging chemotherapies, including multiple chemotherapy or radiotherapy approaches, which remain the backbone of treatment for most cancer patients [6].